All In Biotech

Drug Trial Radar · NCT06193902

LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.

A Phase I/IIa Open-label Dose Escalation Trial Evaluating the Safety and Preliminary Efficacy of LEU011 in Subjects With Relapsed/Refractory Solid Tumours

Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

17

Planned (sponsor's estimate)

Start

Nov 13, 2023

Primary completion

May 2029

Study completion May 2029

Sponsor

Lead sponsor
Leucid BioIndustry
Sponsor type
Industry
First posted
Jan 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a dose-escalation open-label Phase 1/2a study. The purpose of this first-in-human study is to assess the safety and tolerability of LEU011 (autologous CAR T cells targeting NKG2D ligands) in patients with solid tumours.

Conditions

  • Tumor, Solid

Interventions

  • LEU011Biological

    Immunotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the dose limiting toxicity, safety and tolerability of a single dose of LEU011 in subjects with NKG2DL expressing relapsed/refractory solid tumoursTime frame: 28 days post administration of LEU011 immunotherapy
  2. To identify a recommended Phase 2 dose (RP2D) of LEU011Time frame: 28 days post administration of LEU011 immunotherapy

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Guy's and St Thomas' NHS Foundation Trust

    London, United Kingdom · Recruiting

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.